



WEDNESDAY, FEBRUARY 1ST 12:30 - 3:00 PM









FORMAL WELCOME AND ANNOUNCEMENTS - AGENDA

TIME (PM)	ITEM
12:30 - 12:45	Formal Welcome
12:45 – 1:15	Advisory Committee on Immunization Practices Guidelines
1:15 - 1:40	Preteen Vaccine Week 2023: Getting Involved in San Diego
1:40 - 1:50	Announcements
1:50 - 2:05	Break (15min)
2:05 – 2:40	-Vaccine Preventable Disease Update -State Flu Update -San Diego Epidemiology IZ Data
2:40 - 3:00	Vaccines for Children and CAIR2 Updates







FORMAL WELCOME AND ANNOUNCEMENTS

Special Announcement!

ACIP and the Immunization Schedule

MARK H. SAWYER

UCSD SCHOOL OF MEDICINE

RADY CHILDREN'S HOSPITAL SAN DIEGO



Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

o determine minimum intervals betwe	een doses,	see the ca	ten-up sen	edule (Tac	ne z).												
Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2–3 yrs	4-6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17–18 yr:
Hepatitis B (HepB)	1 st dose	← 2 nd (dose		4		3 rd dose										
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1st dose	2 nd dose	See Notes												
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1st dose	2 nd dose	3 rd dose			← — 4 th c	lose			5 th dose					
Haemophilus influenzae type b (Hib)			1st dose	2 nd dose	See Notes		✓3 rd or 4 See N	th dose, Notes									
Pneumococcal conjugate (PCV13)			1st dose	2 nd dose	3 rd dose		← —4 th (dose									
Inactivated poliovirus (IPV <18 yrs)			1st dose	2 nd dose			3 rd dose					4 th dose					
Influenza (IIV4)							Α	Annual vacci	ination 1 or	2 doses			-or -	Annual	vaccination	1 dose onl	у
Influenza (LAIV4)												vaccination 2 doses		Annual	vaccination	1 dose on	у
Measles, mumps, rubella (MMR)					See N	Notes	◄ 1 st 0	dose▶				2 nd dose					
Varicella (VAR)							◄ 1st c	dose▶				2 nd dose					
Hepatitis A (HepA)					See N	Notes	3	2-dose serie	es, See Note	s							
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)														1 dose			
Human papillomavirus (HPV)														See Notes			
Meningococcal (MenACWY-D≥9 mos, MenACWY-CRM≥2 mos, MenACWY-TT ≥2years)								See Notes						1 st dose		2 nd dose	
Meningococcal B (MenB-4C, MenB- FHbp)															See No	tes	
Pneumococcal polysaccharide (PPSV23)														See Notes			
Dengue (DEN4CYD; 9-16 yrs)													Se		n endemic a ee Notes)	reas only	
Range of recommended ages for all children		ecommend ip vaccinati			nge of recon certain high				mended vac gin in this ag			commende shared clin				recommer t applicabl	

Objectives

- Describe the groups most important for developing vaccine policy in the United States
- Talk about the broad input that ACIP receives and what it considers when making recommendations
- Explain where to find information in the CDC vaccine schedule
- Describe some alternative resources for information about the vaccine schedule

ACIP Vaccine Schedule: It's all in there

- The minimum age to give vaccines
- What routine vaccines you may need to be given for international travel
- What high risk conditions are indications to give certain vaccine
- The standard abbreviations used for vaccines
- How to get people caught up who are behind on immunizations
- And more....!

What is in the CDC vaccine schedule

How to use the child and adolescent immunization schedule

Determine: recommended. vaccine by age (Table 1)

Determine recommended interval for catchup vaccination (Table 2)

Assess need for additional recommended vaccines by or other indication (Notes) (Table 3)

Review vaccine types, frequencies, intervals, and considerations for medical condition special situations

Review contraindications and precautions for vaccine types (Appendix)

Who comes up with all this?

Who makes the decisions about what vaccines we give?

- Vaccine manufacturers
- Federal Drug Administration (FDA)
 - Vaccines and Related Biologics Advisory Committee
- Centers for Disease Control (CDC)
 - Advisory Committee on Immunization Practices
- California State Department of Public Health
- Professional Associations
 - American Academy of Pediatrics (AAP)
 - American Association of Family Physicians (AAFP)
 - American College of Obstetrics and Gynecology (ACOG)
 - American College of Physicians (ACP)

These don't always agree!!

ACIP-the early days



ACIP Now





ACIP Structure

- CDC Leadership from NCIRD
- Executive Secretary
- 15 voting members with broad expertise
 - Infectious Disease
 - Pediatrics
 - Family Practice/Internal Medicine
 - Public Health
 - Nursing
 - Community

ACIP Structure-Liaison Members

AAFP

□ACOG

□SAM

□ACHA

□ AGS

AHIP

□APhA

□APTR

□SHEA

HICPAC

■PhRMA

□IHS

DVA

□HRSA

CMS

□NIH

FDA

NVPO

NACCHO

NACI

DOH, UK

NICCHP, Mexico



Considerations for Recommending a New Vaccine

- Burden and risk of disease in the community
- Effectiveness of the vaccine
- Safety of the vaccine
- Cost-benefit analysis
- Feasibility/Vaccine Availability
- Cost/reimbursement for providers
- Patient/parental preferences

It doesn't count until it is published in MMWR!

ACIP Immunization Schedule

General approach

- Give vaccines as early in life as is justified by rates of disease and as early as they will work
- Cluster vaccines at similar ages to facilitate delivery and access
- Provide some flexibility

Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022 These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2). 2 mos Rotavirus (RV): RV1 (2-dose series) 1st dose 2nd dose 2nd dose 3rd or 4th dose, 4th dose Inactivated poliovirus 2nd dose Annual vaccination 1 or 2 doses or or Annual vaccination nfluenza (LAIV4) Annual vaccination 1 dose only <---- 1st dose ----▶ 2-dose series. See Note (Tdap ≥7 yrs) ococcal (MenACWY-D≥9 mos. MenACWY-CRM ≥2 mos, MenACWY-TT See Notes occal B (MenB-4C, MenB-(PPSV23) Dengue (DEN4CYD: 9-16 yrs) on shared clinical decision-making not applicable

Immunization General Principles

- Young children need multiple doses of most vaccines in order to develop a good immune response
- Certain vaccines don't work well in the first two years of life due to maternal antibodies or immaturity of the immune system
- Some vaccines are only important at certain ages (e.g. rotavirus, Hib)
- Minimum ages are very important-doses given before the minimum age need to be repeated
- Maximum ages are a guideline and used by schools to determine status
- You never have to restart a series based on the time since the last dose
- Incomplete series offer incomplete protection

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES

Vaccines in the Child and Adolescent Immunization Schedule*

Dengue vaccine	Tourney Control of the Control of th	
Deligue vaccine	DEN4CYD	Dengvaxia®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel ^e Infanrix ^e
Diphtheria, tetanus vaccine	DT	No trade name
Haemophilus influenzae type b vaccine	Hib (PRP-T) Hib (PRP-OMP)	ActHIB [®] Hiberix [®] PedvaxHIB [®]
Hepatitis A vaccine	НерА	Havrix® Vaqta®
Hepatitis B vaccine	НерВ	Engerix-B ^e Recombivax HB ^e
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IIV4	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II [®]
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D	Menactra®
	MenACWY-CRM	Menveo®
	MenACWY-TT	MenQuadfi*
Meningococcal serogroup B vaccine	MenB-4C	Bexsero®
	MenB-FHbp	Trumenba ^e
Pneumococcal 13-valent conjugate vaccine	PCV13	Prevnar 13°
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23°
Poliovirus vaccine (inactivated)	IPV	IPOL®
Rotavirus vaccine	RV1 RV5	Rotarix ^e RotaTeq ^e
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Tenivac [®] Tdvax [™]
Varicella vaccine	VAR	Varivaxe
Combination vaccines (use combination vaccines instead of sepa	arate injections when ap	propriate)
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®

DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix ^e Quadracel ^e
DTaP, inactivated poliovirus, <i>Haemophilus influenzae</i> type b, and hepatitis B vaccine	DTaP-IPV-Hib- HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

^{*}Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child and adolescent immunization schedule

Determine recommended vaccine by age (Table 1)

Determine recommended interval for catchup vaccination

(Table 2)

Assess need for additional recommended vaccines by medical condition or other indication (Notes) (Table 3)

Review vaccine types, frequencies, contraindications intervals, and considerations for special situations

Review and precautions for vaccine types (Appendix)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Associates (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.-8 p.m. ET, Monday through Friday, excluding holidays



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements:
- www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- ACIP Shared Clinical Decision-Making Recommendations www.cdc.gov/vaccines/acip/acip-scdm-faqs.html



U.S. Department of **Health and Human Services** Centers for Disease Control and Prevention

Scan QR code for access to online schedule




Table 1


Recommended Child and Adolescent Immunization Schedule for a


These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccin To determine minimum intervals between doses, see the catch-up schedule (Table 2).

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos
Hepatitis B (HepB)	1# dose	∢ 2 nd 0	dose				3 rd dose		
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 st dose	2 nd dose	See Notes				
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1" dose	2 nd dose	3 rd dose			◄ 4 th d	ose▶
Haemophilus influenzae type b (Hib)			1 st dose	2 nd dose	See Notes		4 ^{3™} or 4 ¹ See N	^h dose _z Notes	
Pneumococcal conjugate (PCV13)			1 st dose	2 nd dose	3 rd dose		◄ 4 th 0	lose	














Table 1


Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2-3 yrs	4–6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17-18 yrs
Measles, mumps, rubella (MMR)					See N	Notes	4 1* 0	lose				2 nd dose					
Varicella (VAR)							∢ 1# 0	iose>				2 nd dose					
Hepatitis A (HepA)					See N	Notes		2-dose serie	s, See Note	s							-1010
Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)														1 dose			i. i.
Human papillomavirus (HPV)													55	See Notes	3		
















Table 1


Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).


Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos	2-3 yrs	4–6 yrs	7–10 yrs	11–12 yrs	13–15 yrs	16 yrs	17–18 yrs
Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)								See Notes						1* dose		2 rd dose	
Meningococcal B (MenB-4C, MenB- FHbp)															See No	otes	
Pneumococcal polysaccharide (PPSV23)														See Notes			
Dengue (DEN4CYD; 9-16 yrs)													Se		n endemic a	reas only	













Children with high-risk conditions

- Children with high-risk conditions may need vaccines at different ages
 - Meningococcal (MCV) vaccine as young as 2 months of age
 - Pneumococcal polysaccharide (PPSV) at 2 years of age
 - Pneumococcal conjugate (PCV) older than 5 years
- Children with high-risk conditions may need extra doses of vaccine
- Children with high-risk conditions may need to avoid some vaccines
 - MMR, varicella, rotavirus, LAIV, dengue not given to immunocompromised children



Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2022

Always use this table in conjunction with Table 1 and the Notes that follow

	N. Comment				II.	DICATION				
VACCINE	Pregnancy	Immunocom- promised status (excluding HIV infection)	HIV infection <15% or total CD4 cell count of <200/mm ³	CD4+ count ¹ ≥15% and total CD4 cell count of ≥200/mm ³	Kidney failure, end-stage renal disease, or on hemodialysis	Heart disease or chronic lung disease	CSF leak or cochlear implant	Asplenia or persistent complement component deficiencies	Chronic liver disease	Diabete
Hepatitis B										
Rotavirus		SCID ²								
Diphtheria, tetanus, and cellular pertussis (DTaP)										
daemophilus influenzae ype b										
neumococcal conjugate										
nactivated poliovirus										
nfluenza (IIV4)										
or nfluenza (LAIV4)						Asthma, wheezing: 2–4yrs³				
leasles, mumps, rubella	*									
aricella	*									
epatitis A										
etanus, diphtheria, and cellular pertussis (Tdap)										
luman papillomavirus	*									
Meningococcal ACWY]			
Meningococcal B		(
neumococcal olysaccharide										
Dengue										
Vaccination according to routine schedule recommended		Recommended for persons with an addition factor for which the vac would be indicated	onal risk "" ai cine n	accination is recomi nd additional doses ecessary based on r ondition or vaccine.	may be enedical	Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction	recommen not be adm	ated or not ded—vaccine should inistered after pregnancy	No recomme applicable	endation/no

¹ For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, "Altered Immunocompetence," at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.

2 Severe Combined Immunodeficiency

³ LAIV4 contraindicated for children 2-4 years of age with asthma or wheezing during the preceding 12 months


Do children with kidney failure need Haemophilus influenza vaccine above age 5?

Table 3

Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2022


Always use this table in conjunction with Table 1 and the Notes that follow.

INDICATION													
					IN	INDICATION							
			HIV infection	CD4+ count ¹									
VACCINE	Pregnancy	Immunocom- promised status (excluding HIV infection)	<15% or total CD4 cell count of <200/mm³	≥15% and total CD4 cell count of ≥200/mm³	Kidney failure, end-stage renal disease, or on hemodialysis	Heart disease or chronic lung disease	CSF leak or cochlear implant	Asplenia or persistent complement component deficiencies	Chronic liver disease	Diabetes			
Hepatitis B													
Rotavirus		SCID ²											
Diphtheria, tetanus, and acellular pertussis (DTaP)													
Haemophilus influenzae type b													
Pneumococcal conjugate													



Recommended for persons with an additional risk factor for which the vaccine

Precaution—vaccine might be indicated if benefit of protection outweighs risk



Vaccination is recommended, and additional doses may be necessary based on medical

No recommendation/not applicable

What if people are behind?



Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2022

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the Notes that follow.**

			Children age 4 months through 6 years		
Vaccine	Minimum Age for		Minimum Interval Between Doses		
	Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5
Hepatitis B	Birth	4 weeks	8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks		
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	4 weeks maximum age for final dose is 8 months, 0 days		
Diphtheria, tetanus, and acellular pertussis	6 weeks	4 weeks	4 weeks	6 months	6 months
Haemophilus influenzae type b	6 weeks	No further doses needed if first dose was administered at age 15 months or older. 4 weeks if first dose was administered before the 1st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months.	No further doses needed if previous dose was administered at age 15 months or older 4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib®, Pentacel®, Hiberix®), Vaxelis® or unknown 8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1st birthday and second dose was administered at younger than 15 months; OR if both doses were PedvaxHIB® and were administered before the 1st birthday	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 st birthday.	
Pneumococcal conjugate	6 weeks	No further doses needed for healthy children if first dose was administered at age 24 months or older 4 weeks if first dose was administered before the 1st birthday 8 weeks (as final dose for healthy children) if first dose was administered at the 1st birthday or after	No further doses needed for healthy children if previous dose was administered at age 24 months or older 4 weeks if current age is younger than 12 months and previous dose was administered at <7 months old 8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.	
Inactivated poliovirus	6 weeks	4 weeks	4 weeks if current age is <4 years 6 months (as final dose) if current age is 4 years or older	6 months (minimum age 4 years for final dose)	
Measles, mumps, rubella	12 months	4 weeks			
Varicella	12 months	3 months			
Hepatitis A	12 months	6 months			
Meningococcal ACWY	2 months MenACWY-CRM 9 months MenACWY-D 2 years MenACWY-TT		See Notes	See Notes	
			Children and adolescents age 7 through 18 years		
Meningococcal ACWY	Not applicable (N/A)	8 weeks		1	
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	4 weeks	4 weeks if first dose of DTaP/DT was administered before the 1st birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday	6 months if first dose of DTaP/DT was administered before the 1st birthday	
Human papillomavirus	9 years	Routine dosing intervals are recommended.			
Hepatitis A	N/A	6 months			
Hepatitis B	N/A	4 weeks	8 weeks and at least 16 weeks after first dose		
Inactivated poliovirus	N/A	4 weeks	6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.	A fourth dose of IPV is indicated if all previous doses were administered at <4 years or if the third dose was administered <6 months after the second dose.	
Measles, mumps, rubella	N/A	4 weeks			
Varicella	N/A	3 months if younger than age 13 years. 4 weeks if age 13 years or older			



Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2022

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Table 1 and the Notes that follow.

	Children age 4 months through 6 years											
Vaccine	Minimum Age for		Minimum Interval Between Doses									
	Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5							
Hepatitis B	Birth	4 weeks	8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks									
Rotavirus	6 weeks Maximum age for first dose is 14 weeks, 6 days.	4 weeks	4 weeks maximum age for final dose is 8 months, 0 days									
Diphtheria, tetanus, and acellular pertussis	6 weeks	4 weeks	4 weeks	6 months	6 months							

			Children and adolescents age 7 through 18 years	
Meningococcal ACWY	Not applicable (N/A)	8 weeks		
Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis	7 years	4 weeks	4 weeks if first dose of DTaP/DT was administered before the 1" birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1" birthday	6 months if first dose of DTaP/DT was administered before the 1 st birthday
Human papillomavirus	9 years	Routine dosing intervals are		

Polling question

Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the To determine minimum intervals between doses, see the catch-up schedule (Table 2).

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19–23 mos
Hepatitis B (HepB)	1# dose	◄ 2 nd dose >			◄ 3 rd dose					
Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series)			1 st dose	2 nd dose	See Notes					
Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs)			1st dose	2 nd dose	3 rd dose			◄ 4 th dose >		
Haamanhilus influenzaa tuna h (Hih)			1 st doco	2nd doco	San Notae		3rd or 4	dose,		

Can you give DTaP dose #4 at 13 months of age?

- a) Yes
- b) No
- I don't know



Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2022.

Additional information

COVID-19 Vaccination

COVID-19 vaccines are recommended for use within the scope of the Emergency Use Authorization or Biologics License Application for the particular vaccine. ACIP recommendations for the use of COVID-19 vaccines can be found at www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html.

CDC's interim clinical considerations for use of COVID-19 vaccines can be found at www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

- Consult relevant ACIP statements for detailed recommendations at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as "through."
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization at www.cdc.qov/vaccines/hcp/acip-recs/general-recs/timing.html.
- Information on travel vaccination requirements and recommendations is available at www.cdc.gov/travel/.
- For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/ immunocompetence.html, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:67–111).
- For information about vaccination in the setting of a vaccinepreventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.html.

Dengue vaccination (minimum age: 9 years)

Routine vaccination

- Age 9–16 years living in dengue endemic areas AND have laboratory confirmation of previous dengue infection
- 3-dose series administered at 0, 6, and 12 months
- Endemic areas include Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau. For updated guidance on dengue endemic areas and pre-vaccination laboratory testing see www.cdc.gov/dengue/vaccine/hcp/index.html

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])

Routine vaccination

- 5-dose series at age 2, 4, 6, 15–18 months, 4–6 years
- Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
- Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Catch-up vaccination

- Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
- For other catch-up guidance, see Table 2.

Special situations

• Wound management in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/tr/rr6702a1.htm.

Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

Routine vaccination

- ActHIB®, Hiberix®, Pentacel®, or Vaxelis®: 4-dose series (3 dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12–15 months)
- *Vaxelis* is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
- PedvaxHIB*: 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12–15 months)

Catch-up vaccination

- Dose 1 at age 7–11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
- Dose 1 at age 12–14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.

- Dose 1 before age 12 months and dose 2 before age 15 months:
 Administer dose 3 (final dose) at least 8 weeks after dose 2.
- 2 doses of PedvaxHIB® before age 12 months: Administer dose 3 (final dose) at 12–59 months and at least 8 weeks after dose 2.
- 1 dose administered at age 15 months or older: No further doses needed
- Unvaccinated at age 15-59 months: Administer 1 dose.
- Previously unvaccinated children age 60 months or older who are not considered high risk: Do not require catch-up vaccination

For other catch-up guidance, see Table 2. Vaxelis® can be used for catch-up vaccination in children less than age 5 years. Follow the catch-up schedule even if Vaxelis® is used for one or more doses. For detailed information on use of Vaxelis® see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.

Special situations

Chemotherapy or radiation treatment:

Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

- Hematopoietic stem cell transplant (HSCT):
- 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history
- Anatomic or functional asplenia (including sickle cell disease):
 Age 12–59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Unvaccinated* persons age 5 years or older

- 1 dose

Elective splenectomy:

Unvaccinated* persons age 15 months or older

- 1 dose (preferably at least 14 days before procedure)

HIV infection:

Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Unvaccinated* persons age 5-18 years

- 1 dose

Immunoglobulin deficiency, early component complement deficiency:

Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
- *Unvaccinated = Less than routine series (through age 14 months) OR no doses (age 15 months or older)

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix® or Quadracel®])

Routine vaccination

- 5-dose series at age 2, 4, 6, 15–18 months, 4–6 years
 - Prospectively: Dose 4 may be administered as early as age
 12 months if at least 6 months have elapsed since dose 3.
 - Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Hepatitis A vaccination (minimum age: 12 months for routine vaccination)

International travel

- Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel/):
- Infants age 6–11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between age 12–23 months.
- Unvaccinated age 12 months or older: Administer dose 1 as soon as travel is considered.

Influenza vaccination

(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])

Special situations

- Egg allergy, hives only: Any influenza vaccine appropriate for age and health status annually
- Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: see Appendix listing contraindications and precautions
- Severe allergic reaction (e.g., anaphylaxis) to a vaccine component or a previous dose of any influenza vaccine: see Appendix listing contraindications and precautions

Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)

Special situations

International travel

- Infants age 6–11 months: 1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.
- Unvaccinated children age 12 months or older: 2-dose series at least 4 weeks apart before departure

Human papillomavirus vaccination (minimum age: 9 years)

- Interrupted schedules: If vaccination schedule is interrupted, the series does not need to be restarted.
- No additional dose recommended when any HPV vaccine series has been completed using the recommended dosing intervals.

Vaccine trivia

- Does a 6-year-old who has had 3 DTaP doses, the most recent at age 4 years, need a tetanus booster if they step on a nail?
- If a 3yo with leukemia received their last Hib dose 1 week before diagnosis and start of chemotherapy does the dose need to be repeated?
- Can people who get hives when they eat eggs receive egg-based influenza vaccines?
- Can you give a 13yo MMRV?
- Does OPV received in another country in 2019 count for school entry requirements in the U.S.?
- Does a 9yo who receives a Tdap to complete their primary series still need the 11-12yo dose of Tdap?



Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions available at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html and ACIP's Recommendations for the Prevention and Control of 2021-22 seasonal influenza with Vaccines available at www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm.

Interim clinical considerations for use of COVID-19 vaccines including contraindications and precautions can be found at

www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Vaccine	Contraindications ¹	Precautions ²			
Influenza, egg-based, inactivated injectable (IIV4)	 Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) 	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using egg-based IIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever 			
Influenza, cell culture-based inactivated injectable [(ccllV4), Flucelvax* Quadrivalent]	• Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component ³ of ccIIV4	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever 			
Influenza, recombinant injectable [(RIV4), Flublok® Quadrivalent]	• Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component ³ of RIV4	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg- based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Moderate or severe acute illness with or without fever 			
Influenza, live attenuated [LAIV4, Flumist® Quadrivalent]	 Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) Severe allergic reaction (e.g., anaphylaxis) to any vaccine component³ (excluding egg) Children age 2 - 4 years with a history of asthma or wheezing Anatomic or functional asplenia Immunocompromised due to any cause including, but not limited to, medications and HIV infection Close contacts or caregivers of severely immunosuppressed persons who require a protected environment Pregnancy Cochlear implant Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak Children and adolescents receiving aspirin or salicylate-containing medications Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days 	 Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine Asthma in persons aged 5 years old or older Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using LAIV4 (which is egg based), administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)] Moderate or severe acute illness with or without fever 			

- 1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
- 2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
- 3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states

Recommended Adult Immunization Schedule for ages 19 years or older

2022

How to use the adult immunization schedule

Determine recommended vaccinations by age (Table 1) Assess need for additional recommended vaccinations by medical condition or other indication (Table 2) Review vaccine types, frequencies, intervals, and considerations for special situations (Notes) Review contraindications and precautions for vaccine types (Appendix)

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
Haemophilus influenzae type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	НерА	Havrix [®] Vaqta [®]
Hepatitis A and hepatitis B vaccine	НерА-НерВ	Twinrix®
Hepatitis B vaccine	НерВ	Engerix-B [®] Recombivax HB [®] Heplisav-B [®]
Human papillomavirus vaccine	HPV	Gardasil 9°
Influenza vaccine (inactivated)	IIV4	Many brands
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RIV4	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D MenACWY-CRM MenACWY-TT	Menactra® Menveo® MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 15-valent conjugate vaccine	PCV15	Vaxneuvance™
Pneumococcal 20-valent conjugate vaccine	PCV20	Prevnar 20™
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23°
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American Academy of Family Physicians (www.aafp. org), American College of Obstetricians and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Associates (www.aapa.org), and Society for Healthcare Epidemiology of America (www.shea-online.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim is available at www.hrsa.gov/vaccinecompensation.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions):
 www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/surv-manual
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2022: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html



U.S. Department of Health and Human Services Centers for Disease Control and Prevention Scan QR code for access to online schedule



CS310021-A

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2022

Vaccine	19–26 years	27-49 years		50-64 years	≥65 years					
Influenza inactivated (IIV4) or Influenza recombinant (RIV4)	1 dose annually									
Influenza live, attenuated (LAIV4)	1 dose annually									
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes) 1 dose Tdap, then Td or Tdap booster every 10 years									
Measles, mumps, rubella (MMR)										
Varicella (VAR)	2 doses (if born in 1980 o	or later)		2 doses						
Zoster recombinant (RZV)	2 doses for immunocompron	nising conditions (see notes)		2 doses						
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years								
Pneumococcal (PCV15, PCV20, PPSV23)		1 dose PCV15 followed by PPSV23 OR 1 dose PCV20								
Hepatitis A (HepA)	1 dose PCV20 (see notes) 1 dose PCV20 2 or 3 doses depending on vaccine									
Hepatitis B (HepB)	2, 3, or 4 doses depending on vaccine or condition									
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations									
Meningococcal B (MenB)	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations 19 through 23 years									
Haemophilus influenzae type b (Hib)	1 or 3 doses depending on indication									

lack documentation of vaccination, or lack evidence of past infection

additional risk factor or another indication

clinical decision-making


Not applicable


Table 2 Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2022


Vaccine	Pregnancy	lmmuno- compromised (excluding HIV infection)		tion CD4 and count ≥15% and ≥200 mm³	Asplenia, complement deficiencies	End-stage renal disease, or on hemodialysis	Heart or lung disease; alcoholism¹	Chronic liver disease	Diabetes	Health care personnel ²	Men who have sex with men			
IIV4 or RIV4		1 dose annually												
LAIV4		Coi	ntraindicated				1 dose annually							
Tdap or Td	1 dose Tdap each pregnancy													
MMR	Contraindicated*	Contrainc	licated			1 or 2 doses depending on indication								
VAR	Contraindicated*	Contrainc	licated			2 doses								
RZV		2 dose	s at age ≥19 ye	ears	2 doses at age ≥50 years									
HPV	Not Recommended*	3 doses th	rough age 2	б years	2 or 3 doses through age 26 years depending on age at initial vaccination or condition									
Pneumococcal (PCV15, PCV20, PPSV23)		1 dose PCV15 followed by PPSV23 OR 1 dose PCV20 (see notes)												
НерА		2 or 3 do <mark>ses depending</mark> on vaccine												
НерВ	3 doses (see notes)	2. 3. or 4 doses depending on vaccine or condition												
MenACWY	1 or 2 doses depending on indication, see notes for booster recommendations													
MenB	Precaution	Precaution 2 or 3 doses depending on vaccine and indication, see notes for booster recommendations												
Hib		3 doses HSCT ³ recipients only			1 dose									
Recommended va for adults who me age requirement, documentation of vaccination, or lac evidence of past in	for adults with an additional based on shared decision-making indication ck					Precaution—vacc might be indicate benefit of protect outweighs risk of reaction	ed if tion	Contraindicated or recommended—v should not be adn *Vaccinate after pr	raccine ninistered.	No recommendation/ Not applicable				

1. Precaution for LAIV4 does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.

What the colors mean








No recommendation/ Not applicable


Everyone Give this vaccine if specific	c risk You and your patient	Not
factors are present	decide	recommended


Should a 30yo person get HPV vaccine?

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2022

Vaccine	19-26 years	27–49 years	50–64 years	≥65 years	
Zoster recombinant (RZV)	2 doses for immunocompro	mising conditions (see notes)	2 doses		
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years			
Pneumococcal (PCV15, PCV20, PPSV23)	1 dose PCV15 followed by PPSV23 OR OR 1 dose PCV20 (see notes) 1 dose PCV15 followed by PPSV23 OR 1 dose PCV20				
Hepatitis A	2 or 3 doses depending on vaccine				









Tune in!!

- Next meeting is February 22-24, 2023
- https://www.cdc.gov/vaccines/acip/meetings/index.html
 - Agenda
 - Webcast (live and recorded)
 - PowerPoint presentations
 - Public Comment

What's coming in 2023

- PCV20 for children
- RSV vaccine for seniors
- Combined Meningococcal ACWY and Men B vaccine
- Chikungunya vaccine
- New approach to COVID vaccines
 - Harmonization of primary series and booster vaccines composition
 - Reduced number of doses for the primary series, at least for low-risk populations
 - Updated strain selection in May-June for the upcoming fall
 - ?annual boosting

Resources

- CDC: https://www.cdc.gov/vaccines/
- CDPH: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/immunize.aspx
- SD Immunization Branch: http://www.sdiz.org/
- Immunization Action Coalition: https://www.immunize.org/
- CHOP Vaccine Education Center: https://www.chop.edu/centers-programs/vaccine-education-center

Summary

Immunizations are an important public health intervention

Policy making and communication about immunizations is challenging

The CDC immunization schedule is the primary road map for negotiating complicated vaccine administration questions

CDC, CDPH, San Diego HHSA Immunization Branch have excellent resources online



Preteen Vaccine Week 2023: Getting Involved in San Diego


Margaux Stack-Babich, MPH
Community Outreach and Engagement Coordinator
UCSD Moores Cancer Center

Slide Authors: California Department of Public Health

Agenda

- What is Preteen Vaccine Week?
- Update on Adolescent Immunization Coverage
- PVW 2023
 - Getting Involved in San Diego

What is Preteen Vaccine Week?



- Annual observance to promote the preteen doctor visit & raise awareness about routinely recommended immunizations for preteens
- School requirements:
 - Tdap
 - Chickenpox

Who?

- Local Health Jurisdictions
- Coalitions
- Schools
- Medi-Cal Managed Care Plans
- Other partners

Why?

- Organize planning
- Learn about tools and resources
- Unified approach = amplified
- Share ideas with each other for PVW and beyond

Where?

- Health departments
- Schools
- Provider offices

- Health fairs
- Partner organizations
- Social media

UPDATE ON ADOLESCENT IMMUNIZATION COVERAGE

Estimated vaccination coverage: Adolescents aged 13-17 years

	Fem	ales	Males				
	≥1 HPV	HPV UTD	≥1 HPV	HPV UTD	≥1 Tdap	≥1 Men ACWY	≥2 Var
Healthy People 2030 Objective (13-15 years)		80%		80%	removed	removed	removed
US 2021	79%	64%	75%	60%	90%	89%	92%
CA 2021	81%	67%	83%	71%	89%	87%	88%
CA 2020	83%	69%	73%	56%	90%	85%	86%
Source: NIS-Teen, US, 2021 & 2020							


Immunization Deficit During the Pandemic

Tdap in 11-to-13-Year-Olds*

Compared with 2019

- In 2020, there was a 21% deficit (-79,508/378,290)
- In 2021, there was an 8% surplus (31,997/378,290)
- In 2022, there was a 5% deficit (-19,995/184,355)






Immunization Deficit During the Pandemic

MenACWY in 11-to-13-Year-Olds*

Compared with 2019

- In 2020, there was a 20% deficit (-80,998/394,389)
- In 2021, there was a 1% deficit (-3,569/394,389)
- In 2022, there was a 14% deficit (-56,063/394,389)






Immunization Deficit During the Pandemic

HPV vaccine in 11-to-13-Year-Olds*

Compared with 2019


- In 2020, there was a 19% deficit (-69,140/365,730)
- In 2021, there was a 1% deficit (-2,462/365,730)
- In 2022, there was a 14% deficit (-52,311/365,730)





Proportion Initiating HPV Vaccination at Age 9 or 10 Years

Among 9-to-15-year-olds*




^{*} Proportion who were 9 or 10 years old at series initiation, comparison by year, of adolescents aged 9-15 who received their 1st does during the calendar 52 year,, 2018-2022. Source: CAIR2

9 Benefits to Starting HPV Vaccination at Age 9

- 1. More time to complete the series by 13
- 2. Strong immune response
- 3. Vaccinate before exposure
- 4. Decreases questions about sexual activity from parents
- 5. Decreases requests for only school-required shots
- 6. Decreases number of shots administered per visit
- 7. Increases # of vaccinations, and therefore number of cancers prevented
- 8. Shown to increase vaccination rates
- 9. Highly acceptable to systems, providers, and parents

COVID-19 Vaccination Status by Age Group

Vaccinated Status by Group of Total CA Population



Source: https://covid19.ca.gov/vaccination-progress-data/#overview



Protect Their Health for the Years Ahead

Preteen Vaccine Week February 26-March 4, 2023

PRETEEN VACCINE WEEK 2023

PVW 2023

- February 26 March 4
- School-located vaccination events
- HPV vaccine starting at 9 years
- Find campaign resources at QR code or: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/Campaigns.aspx#



Updated Resources







Vaccines for Your Preteen

Learn about vaccines to help your preteen stay healthy through adolescence and beyond.

Vaccine recommendations for 11-12 year olds

Tdap protects against tetanus, diphtheria, and pertussis (whooping cough). Whooping cough can cause vomiting, gasping for air, and trouble sleeping. It may last for months and is very contagious. This vaccine is required or 7[™] grade entry in California.

HPV (human papillomavirus) vaccine series is recommended starting at age 9. It prevents warts and several cancers of the reproductive system, as well as throat and mouth cancer. HPV vaccine works best when given during the preteen years. Preteens who are vaccinated earlier need only two shots

Meningococcal vaccines protect against bacterial meningitis, a very serious infection that can lead to brain damage, arm and leg amputations, kidney damage, and death. Preteens need to get immunized now and

Flu (influenza) vaccine is needed every year. Flu is much more serious than the common cold. Even healthy young people can get the flu. Children with chronic conditions like asthma and diabetes are especially at risk for pneumonia or even death.

Chickenpox vaccine protects against more than just an itchy rash. The disease can cause pneumonia or serious skin infections. Preteens need two shots before starting 7™ grade.

COVID-19 vaccine can protect against serious illness in everyone 6 months and up, including preteens. Preventing COVID-19 infection can mean less time away from school, sports, and social activities.

? Ask the Doctor

☐ HPV

[FLV

MENINGOCOCCAL

☐ CHICKENPOX

COVID-19

- Does my child need any other catch-up shots (e.g., MMR, chickenpox, and hepatitis B)?
- Are there any side effects from these vaccines?
- Which vaccines are required for school, and can you give me the documentation I need?
- ▶ Will any other shots be needed later on?
- ► Can I get an updated shot record?
- Can I schedule my child's next HPV shot(s) today?

ShotsForSchool.org

California Department of Public Health Immunization Branch - 850 Marine Boy Pkwy - Richmond CA 94804





PROTECT Their Health for the Years Ahead



including whooping cough.

Even healthy young people can get the flu



Protect Your Preteen/Teen with Vaccines

Protect them from serious diseases including HPV cancers, meningitis, tetanus, whooping cough, flu, and COVID-19.



AGES 9 - 10

- HPV dose 1 (human papillomavirus)
- · HPV dose 2 (6 12 months after dose 1)

AGES 11 - 12

- Meningitis dose 1 (MenACWY)
- · Tdap (tetanus, diphtheria, pertussis)
- HPV (if 2 doses haven't been given)

AGE 16

- Meningitis dose 2 (MenACWY)
- · Meningitis B series (MenB)

YEARLY

· Flu (seasonal influenza)

Preteens and teens should stay up-to-date with COVID-19 vaccine to help protect them from COVID-19.





has soly Connectified Assessment count to enhance WINGERSANCET The content of this recitionism closes of necessarily represent the official views of, nor an endorsement by, the CDC/1915 or the U.S. Cor.


IMM-1447 57 **IMM-1054**

Updated Resources











Translated Resources

- Spanish
- Chinese
- Hmong
- Russian
- Tagalog
- Ukrainian







point in their life, but most won't know when they have it.

HPV infections can cause cervical cancer in women and penile cancer in men.

HPV can also cause throat and mouth cancer, anal cancer, and genital warts in

But, you can help protect your child from these cancers with the HPV vaccine.

IMM-1054

IMM-1448

IMM-1124


both men and women.

Misinformation Resources

- Vaccine Safety: Answers to Parents' Top Questions (CDPH, <u>English</u> | <u>Spanish</u> | <u>Russian</u>)
- HPV Vaccination: Just the Facts (ACS, for parents <u>English</u> | <u>Spanish</u>)
- HPV Vaccination: Just the Facts (ACS, for <u>providers</u>)
- <u>Vaccination Communication: Inoculating Against</u>
 <u>Misinformation</u> (California Immunization Coalition & San Diego PATH)
 - Follow-up Q&A session Tuesday, January 31st at noon (coming soon)

Order Materials for PVW 2023

If you're interested in ordering materials for Preteen Vaccine Week, visit https://www.sandiegocounty.gov/conte nt/sdc/hhsa/programs/phs/immunizati on-branch/IZ Materials.html and click on the Request Materials button or e-mail izinfo.hhsa@sdcounty.ca.gov



Stay Tuned for Vaccine Promotion and Clinics in the SD Community - Consider Hosting An Event!

Campaign Kit

Preteen Vaccine Week 2023



Campaign Kit ebruary 26 – March 4, 2023

- Action Plan
- Preteen Vaccine Week Order Form Template
- Talking Points
- Suggested Activities
- Social Media Messages
- Press Release
- Healthcare Provider e-Blast
- School Staff e-Blast
- Letter from School Nurse to Parents
- Template Proclamation
- Appendix: Resources and web links



Suggested Activities

Social Media and Traditional Media Activities

- Update your website
 Post on social media
- Share materials electronically Distribute printed PVW materials

Activities to Engage Providers

- Encourage use of R/R
- Host IZ update seminar

- Encourage providers to vaccinate against HPV at age 9
- **Activities to Engage Schools**
- Listserv notice to parents
- Show how to use CAIR

- Attend school nurses meeting
- Hold school-based vaccination clinic

Activities to Engage Other Partners


Partner with WIC

Library display


- ☐ Least time-consuming
- ☐ Activities that require some time and/or resources
- ☐ Most time-consuming

Suggested Social Media Messages


Monday,
February 27
General
Awareness




Tuesday, February 28 COVID-19



Wednesday,
March 1
Whooping
Cough



Thursday, March 2 Meningitis



Friday, March 3 HPV



#PreteenVaxCA

ADDITIONAL ANNOUNCEMENTS





Reasons to join:

Connections! Collaboration! Community!

SDIC Steering Committee members help make thoughtful decisions for SDIC's meeting topics, biannual summits, short-and long-term goals, branding, and other activities that support SDIC's mission statement.

If you would like to volunteer as an SDIC Steering Committee member for 2023, please email Cynthia.To@sdcounty.ca.gov

Visit sdizcoalition.org for more information!



SAN DIEGO

ADDITIONAL ANNOUNCEMENTS

















UP NEXT...

- Vaccine Preventable Disease Program Updates
- State Flu Updates
- San Diego Epidemiology Updates
- Vaccines for Children and CAIR2 Updates





- Vaccine Preventable Disease Program Updates (15min)
- State Flu Update (10min)
- San Diego Epidemiology IZ Data (10min)
- Vaccines for Children and CAIR2 Updates (15min)



SDIC SERVICE DELIVERY IMMUNIZATION VACCINE PREVENTABLE DISEASES PROGRAM

CLINICAL TEAM UPDATE

FEBRUARY 1, 2023

Masha Djuric, RN, PHN Supervisor







PROGRAM UPDATE




IMMUNIZATIONS

Vaccine Preventable Diseases PROGRAM		VACCINE PROGRAM		
1	PHN Supervisor	1	PHN Supervisor	
1	QAS	2	QAS's	
3	Senior PHN's	2	Senior PHN's	
4	PHN's	4	PHN's	
2	School workforce grant RN's	2	Vaccine Support	
2	Senior HIMT			
2	HIMT (Vacant)			
2	Clinical Support			





Immunization Unit (sandiegocounty.gov)



ENHANCED BY Google





MENU 🗸

PROGRAMS

ALL SERVICES A-Z

FACILITIES

ADVISORY BOARDS

CONTACT US

Immunization Unit













The San Diego County Immunization Unit's mission is to eliminate vaccine-preventable diseases by improving vaccine coverage for all San Diegans. Our tools are disease investigation and control, education, community collaboration, health and vaccine assessments, school law, and the California Immunization Registry.

Relevant California Health and Safety Code Sections include 120100-122420, 120325-120380, and 120400-120435.

Did you receive a call about a study on immunizations?—Learn More!

Fight the Flu 2022-2023 Seasonal Influenza Materials



Immunization Unit Navigation Menu

> Immunization Home Page

Vaccines for All Ages and Stages

Immunization Requirements for Child Care and TK/K-12 Schools

Seasonal Influenza-Flu

- Flu Vaccine Locations
- Sitios de Vacunas
- Flu Resources and Materials
- Guidance for High Risk Groups
- Health Conditions and Flu Complications
- Healthcare Personnel Flu Season Mandates

Immunization
Clinic Locations

California Immunization Registry (CAIR2) San Diego

State-Funded Influenza Vaccine Program

Digital Vaccine Record (ca.gov)



State of California

English Español 简体字 MORE 🗸



Welcome to the Digital Vaccine Record (DVR) portal

Get a digital copy of your vaccine record. Just enter a few details below to get a link to your COVID-19 Vaccine Record with a QR code or your California Immunization Record. Save it on your phone and use it as proof of vaccination wherever you go.

If you are a parent or guardian and have multiple vaccine records associated with a single cell phone number or email address, enter each Digital Vaccine Record request separately.

NOTE: It is possible that some or all vaccine doses you received were not reported to the California Immunization Registry (CAIR), and therefore your Digital Vaccine Record may not be complete. Historically, only COVID-19 vaccinations were required to be reported to CAIR and effective January 1, 2023, all vaccines are required to be reported.

If you received your vaccinations from a federal agency (e.g., Department of Defense, Indian Health Services, or Veterans Affairs), you may need to contact those agencies for assistance with your vaccination record.

If you have questions about your vaccination record, visit our FAQ.

Please select from one of the options below:

- O I want my COVID-19 Vaccine Record with QR code
- O I want my California Immunization Record
- O I want both









San Diego County Respiratory Virus Surveillance Report

Prepared by Epidemiology and Immunization Services Branch <u>www.sdepi.org</u>

January 26, 2023

COVID-19

133,683

Deaths 305

Outbreaks*

7/3/2022 - 1/21/2023

Influenza

Cases 20,638

Deaths 39

Outbreaks*

22

7/3/2022 - 1/21/2023
*In residential congregate settings

Report Content Links

- Page 2: COVID-19 and Influenza Fiscal Year-to-Date Overview
- Page 3: COVID-19 and Influenza Cases by Episode Week, Fiscal Year-to-Date
- Page 4: Cumulative COVID-19 and Influenza Cases
- Page 5: COVID-19 and Influenza Case Trends Over Time
- Page 6: Emergency Department Data: COVID-like Illness and Influenza-like Illness
- Page 7: Monthly COVID-19 Cases, Hospitalizations, and Deaths by Age
- Page 8: Influenza Case Counts by Age
- Page 9: COVID-19 and Influenza Outbreaks and Co-Infections
- Page 10: COVID-19 and Influenza Deaths
- Page 11: Summary of Deaths, Fiscal Year-to-Date
- Page 12: Vaccinations Administered
- Page 13: COVID-19 Hospitalizations and Deaths by Vaccination Status
- Page 14: Wastewater Surveillance
- Page 15: COVID-19 Surveillance on Variants
- Page 16: Respiratory Syncytial Virus (RSV) Surveillance

Please visit the COVID-19 data dashboards on the County of San Diego COVID-19 website. Additional COVID-19 data are available there in a more interactive format.


Most data in this report are presented by fiscal year, which runs July 1–June 30. Because data are also presented by CDC disease week, which runs Sunday–Saturday, we start the data for 2022-23 on July 3, 2022.

Epidemiology and Immunization Services Branch www.sdepi.org (619) 692-8499

2022 VPD DATA



Select Vaccine-Preventable Infections by Month, 2022-23 YTD*




^{* 2023} data are year to date; current as of 01/27/23. Case counts are provisional and subject to change as additional information becomes available. Cases are grouped into calendar months and calendar years on the basis of the earliest of the following dates: onset, lab specimen collection, diagnosis, death, and report received. Counts may differ from previously or subsequently reported counts due to differences in inclusion or grouping criteria, late reporting, or updated case information. Inclusion criteria (C,P,S = Confirmed, Probable, Suspect) based on Council of State and Territorial Epidemiologists/Centers for Disease Control and Prevention (CSTE/CDC) surveillance case criteria. Prepared by County of San Diego, Health & Human Services Agency, Public Health Services, EISB.

PERTUSSIS



San Diego County Pertussis Annual Total Cases by Year of Onset, 2000-2023 YTD*




^{* 2023} data are year to date; current as of 01/27/23. Case counts are provisional and subject to change as additional information becomes available. Cases are grouped into calendar months and calendar years on the basis of the earliest of the following dates: onset, lab specimen collection, diagnosis, death, and report received. Counts may differ from previously or subsequently reported counts due to differences in inclusion or grouping criteria, late reporting, or updated case information. Inclusion criteria (C,P,S = Confirmed, Probable, Suspect) based on Council of State and Territorial Epidemiologists/Centers for Disease Control and Prevention (CSTE/CDC) surveillance case criteria. Prepared by County of San Diego, Health & Human Services Agency, Public Health Services, EISB.

PERTUSSIS IN SCHOOLS



33 Pertussis school notifications sent in 2022-2023 YTD



أعزاءنا الوالدين/الأوصياء

لقد لوحظ مصرال حالة) حالات من مرضن السحال الديكي(pertussis) في مدرسقا/ الرحاية الصحية / صفوقنا افرقاقا. مضمقان اين كون مظاكم قد تعرض لهذا العرض الشديد اليوجيق والكو يسبب سمات ثميد به أ. لا يوجد القاح وقال ناجع ٤٠٠٠ ، و لهذا على الأشخاص المحمسين الالقعين معرضين بالإصابة يعرض السمال الديكي ولكن الأحراض يؤكين عادة الل حدة.

أن السعال الديكي ينتشر عن طريق اليواء عندما يعطس أو يسحل الشخص الفريض. أن الأطفال الرضع و الصخار بالعمر معرضين) الإنف، عمى خفيفة، والسعال بين

Fecha:

RE: EXPOSICIÓN A LA TOS FERINA

Estimado padre/tutor:

Estimado padre tu د اسبوعین او اکثرو قد یصحبیا

Ha habido un(os) caso(s) de tos ferina en muestro/a escuela/guarderia/salón/equipo. Su hijo/a pudo haber sido expuesto/a a esta enfermedad sumamente contagiosa que causa tos severa. Ya que ninguna vacuna protege al 100% sum las narsonas vacunados madan anfarmarsa da tos ferina, pero los sintomas regularmen

يتم التعامل مع هذا المرض

الاطفال المرضى في المنزل لمين

لطفال) أو لقاح Tdap (للمراهقين

<u>Immunization Pros.</u> ديكي ، يتبغي تحديد مو عد الأطفالهم

بالمرض بعد احتكاكه بشخص

(تسانية ، خدمات علم الأويئة و

La tos ferina se propaga por el aire cuan pequeños corren el mayor peligro contra enfermedad. Los sintomas regularments nariz, fiebre ligera y tos ocasional. La tr podrian resultar en:

- un chillido agudo al inhalar aire
- vómito o arcadas
- ahogo o ponerse morado/a

En niños más grandes y adultos, los sint que duran dos semanas o más y pueden: pegajoso. Estos ataques pueden empeor puede sentir bien y no tener sintomas.

Si su hijo/a comienza a desarrollar sinto

- Consulte a su médico e infórme
 con tos ferina. Esta enfermedad
- Notifiquele a la escuela si su do niños/as enfermos/as deben pen de antibióticos para evitar conta

Para ayudar a proteger contra la tos ferir 1. Consulte con su doctor para ver

- apropiada de vacunas de DTaP (
 2. Lávense las manos frecuentemes
- Visite los sitios <u>Whooping Coug</u> (sandiegocounty.gov) para aprex
- Los padres de niños sin sintoma: contra la tos ferina, pueden cons profilaxis después de ser expues con una persona con tos ferina p

Si tiene más preguntas sobre la tos ferin: Agencia de Salud y Servicios Humanos presione la tecla numero 5 para hablar c electrónico a PHS-IZPHN.HHSA@sdcc

Atentamente

RE: PERTUSSIS EXPOSURE

Dear Parent/Guardian,

There has been a case of Pertussis (Whooping Cough) in [Name of facility]. Your child may have been exposed to this highly contagious disease that causes severe coughing. Because no vaccine is 100% protective, even immunized persons can become ill with pertussis, but the symptoms are usually milder

Please notify your child's doctor if your child develops symptoms of pertussis. Notify the childcare if your doctor suspects your child is ill with pertussis. Ill children should stay home until completion of five days of antibiotic therapy to prevent spreading the disease to others.

About Pertussis

Pertussis is spread through the air when an ill person coughs or sneezes. Infants and young children are at highest risk of life threatening complications from the disease. Their symptoms most often include cold symptoms such as runny nose, slight fever, and occasional cough. The cough becomes worse, turning into coughing spasms that may be followed by:

- · a crowing (whooping) sound on breathing in
- vomiting or gagging
- choking or turning blue

In older children and adults, pertussis symptoms include aggravating coughing attacks that last for two weeks or longer and may be accompanied by vomiting, gagging, and sticky mucus production. These attacks may worsen at night. Between the coughing attacks, the person may feel well and have no symptoms.

To help protect against getting ill from Pertussis:

- Check with your doctor to see if your child is up to date with the appropriate number of DTaP
 (childhood) vaccine doses. Your child should continue to get their vaccines as recommended on
 the vaccination schedule. If your child is behind on their vaccinations, they should be placed on a
 catch-in schedule.
- Teenagers and adults need a Pertussis booster Tdap, too. People 10 years and older should receive one Tdap vaccination.
- 3. Wash hands frequently.
- Visit the websites <u>CDC</u> <u>Whooping Cough (Pertussis)</u> or the <u>Immunization Program (sandiegocounty.gov)</u> to learn more about pertussis.

If you have any additional questions regarding pertussis, you may call the County of San Diego Health and Human Services Agency, Immunization Branch at (366) 358-2966 and press 5 to speak with a Public Health Murse or email PHS-ICPHN-HHSA@sdcounty.ca.gov.

incerely,

SCHOOL WORKFORCE GRANT





PURPOSE

Increase immunization rates in school-aged children

PLANNED TASKS AND ACTIVITIES

- Education of students and families
- Education of school administration
- Education of school health personnel
- Immunization events (PODs)
- Collection of data



IMMUNIZATION SKILLS INSTITUTE (ISI)





Immunizations Skills Institute (ISI)

The Immunization Skills Institute (ISI) is handson training to assist with medical assistants and other allied health care professionals on storage, handling, and administration of vaccines in collaboration with Public Health Nurses in the San Diego County.



Presented by the County of San Diego - Health & Human Services





VPD PROGRAM CLINICAL TEAM





- Masha Djuric, PHN Supervisor
 Maria.Djuric@sdcounty.ca.gov
- Stephanie Daniels, RN QAS
 Stephanie.Daniels@sdcounty.ca.gov
- Fadumo Ismail, Senior PHN
 Fadumo.lsmail@sdcounty.ca.gov
- Yasmin Gaddum, Senior PHN
 Yasmin.Gaddum@sdcounty.ca.gov
- Kevin Mendoza, Senior PHN
 Kevin.Mendoza@sdcounty.ca.gov
- Rachel Jonas, PHN
 Rachel.Jonas@sdcounty.ca.gov
- Sammie Fezzey, PHNSamantha.Fezzey@sdcounty.ca.gov
- Raquel Blackshere, PHN
 Raquel.Blackshere2@sdcounty.ca.gov
- Emma King, PHNEmma.King@sdcounty.ca.gov

CLINICAL SUPPORT

- Maria Arevalo, Senior HIMT
 Maria.Arevalo@sdcounty.ca.gov
- Alyssa Gomez, Senior HIMT
 Alyssa.Gomez1@sdcounty.ca.gov
- Adriana Cruz, Clinical Assistant
 Adriana.Cruz@sdcounty.ca.gov
- Patty Novoa, Clinical Assistant
 Patricia.Novoa@sdcounty.ca.gov

SCHOOL WORKFORCE GRANT

- Francesco Cortez, Agency RN
 Francesco.Cortez@sdcounty.ca.gov
- Melissa Simon, Agency RN
 <u>Melissa.Simon@sdcounty.ca.gov</u>

Immunization VPD Program disease reports and inquiries are made:

Monday-Friday 8am – 5pm: Immunization PHN Line 866-358-2966 option 5 or by sending an email to PHS-IZPHN.HHSA@sdcounty.ca.gov





After-hours, weekends & holidays: 858-565-5255

QUESTIONS





RESOURCES



- All Diseases and Conditions (ca.gov)
- Ask the Experts: Experts Answer Questions About Vaccines (immunize.org)
- Data and Reports (sandiegocounty.gov)
- Digital Vaccine Record (ca.gov)
- Epidemiology Program (sandiegocounty.gov)
- Immunization Program (sandiegocounty.gov)
- SDIC Home (sdizcoalition.org)
- Shots for School (ca.gov)







STATE FLU VACCINE PROGRAM UPDATES

February 1, 2023

Araceli Montera, MPH

State Flu Vaccine Admin Coordinator



THANK YOU!



- Continued Partnership in the State-Funded Flu program
- Promoting flu vaccination and Vaccinating the Community
- Weekly report to email:HHSA.countyfluvaccine@sdcounty.ca.gov
- CAIR : Data Entry
 - CAIR Help Desk

Phone: 800-578-7889

Email: CAIRHelpDesk@cdph.ca.gov.

Hours are 8:00 a.m. - 5:00 p.m. Monday - Friday,




CURRENT INVENTORY



INVENTORY ON HAND: 350 DOSES / 35 BOXES

DISTRIBUTION Afluria MDV Fluarix SYR Total # doses distributed to providers 7050 44,180 51230 CHCs and CBOs 4050 37,130 41180 3000 3510 PHCs 510 CalFire, Mass Vax & Pods 0 6,540 6540 # of doses remaining to distribute 350 350



CURRENT INVENTORY



- ✓ Allocated vaccine is 100%
- ✓ If you require more vaccine, email requests to HHSA.countyfluvaccine@sdcounty.ca.gov
 - ✓ We request that your overall usage be at 90% or higher
- ✓ Provider that are part of an organization, Redistribute among sister sites.
 - ✓ If you need assistance to transfer outside your organization, please work with the program to assist with coordination
 - ✓ Vaccine redistribution: Extra vaccine on hand or limited vaccine

	Afluria MDV		Fluari	x SYR	Total		
	#	%	#	%	#	%	
doses received from State	7,050	100%	44,530	100%	51,580	100%	
doses allocated	7,050	100%	44,530	100%	51,580	100%	
doses remaining to distribute ⁵	-	0%	350	1%	350	1%	
doses administered ⁶	5,729	81%	37,072	86%	42,801	85%	
doses wasted ⁷	344	5%	601	1%	945	2%	
doses with Providers	977	14%	6,507	15%	7,484	15%	

^{*}The % total indicates average from the total doses received

^{5.} The amount of doses remaining to distribute.

^{6.} The amount of doses administered based on the weekly reports. The denominator of the percentage is the total # of doses that providers have received.

^{7.} The amount of doses wasted based on the weekly reports. The denominator of the percentage is the total # of doses that providers have received.

WEEKLY REPORT



REMINDER

- Fill out the date range Monday Sunday dates only
- Remove old information / Reported data
- Document vaccine transfer for events or outside of your clinic. Include the clinic name and person name.
- Weekly manual count of flu vaccine and this matches the inventory on the weekly report
- CAIR users:
 - ✓ Add new vaccine Inventory & funding source must be "State General Fund"
- Weekly Report on sandiegocounty.gov website
 State-Funded Influenza Resource Page.

# HHS	State-Purchased Influenza Vaccine Program Weekly Report 2022-2023																
■ CAIR Dose administered Report* ■ Digital Data logger report																	
Refrigerator temperature log *Interface providers only: Encrypted patient list in .xlsx/.csv format. Include patient name, DOB, vaccine name & lot #, vaccination date and the administered clinic name.																	
POD		Region					Reporting week 9/12/2022 _ 9/18/2022										
Org	anizati	on				Faci	lity	y/S	ite			L	Monday Sunday				
				rec													the reporting week
Date		duct Name	Lot #		Qua	intity	Received or transferred Received from B			Site received from or Site transferred to							
9/13/2022	F	luarix	123AE	3C	20	00	ļ		Transferre	d t	o C			COC Warehouse			ouse
9/14/2022	F	luarix	123AE	3C	50		×					Event name 1					
9/15/2022	F	luarix	123AE	123ABC		20		Received from Transferred		d t	• C	Event Name 2			ne 2		
9/16/2022	F	luarix	123AE	123ABC		50		Received to				Event Name 3		ne 3			
9/16/2022	F	luarix	ABC4	2421 200				Received from B Transferred to C			COC Warehouse						
9/16/2022	F	luarix	ABC4	21	21 10 Received from Transferred							PHC Region					
Vaccine Usag	e- Cou	int of vaccines	s administe	red,	per ag	ge group	p j	for	main clin	<u>c</u> u	se only	if applic	cabl	e. Do no	ot in	clude of	f-site usage here.
Product na	Product name Lot # 6-35 mo		3	3-6 yr 7-18		yr 19-49		19-49 yr	50	0-59 yr 60-64				es used			
Fluario	(123ABC	0		5	9			1		8	5		2	3	30	D
Fluario	(ABC421	0		0	0		4	0		0	0		0	()	D
								4									D
																	D
Vaccine Inve	ntory-	Physical inver	ntory count	* of			at	t th	e end of t	he	reportir	ng week	(A+	B-C-D-I	E+F=	Number	of doses on hand)
Product name		Lot#	Last week Number o	of (- ,		transferred admi							_	ra doses DV only)	Number of doses on hand*	
			doses on hand*	'							Do NOT inc		E E		re F	end of the week (Monday-Sunday)	
Fluarix			00	120			3	30		0	0		50				
Fluarix ABC421		0	1	200		10				0		0			0	190	
				4			L										
Do not uso this		for temperatu	ro evalerion	- En	nail dos	umente			HSA Counts	El.	Vaccine	@sdcou	ntv c	3 anu *	rono	et lookuu	ASAP

TIPS FOR SPEAKING ABOUT THE FLU VACCINE





- I heard the Flu shot can give you the flu.
- I was vaccinated last year and still got sick
- I'm Concerned about side effects.
- I don't care so much about flu since
 COVID-19.



Tips for Speaking with Parents about Flu Vaccine

How to Address Common Concerns

I heard the flu shot can give you the flu.

- Flu vaccines are made with killed or weakened viruses that cannot give you the flu.
- Sometimes the body's immune response after vaccination can make some people feel a little ill, and that's normal.
 For example, some kids may get a slight fever, but that's their body building antibodies to protect them from flu.

My child got vaccinated last year and still got sick.

- Many other germs cause symptoms similar to flu-your child might have caught one of them.
- Flu vaccine takes 2 weeks to work. Your child may have caught flu/a virus before developing immunity.
- Flu vaccines are not 100% effective. However, even if your child catches the flu, the illness will be much less severe.

Flu vaccine is not effective. Why bother?

- Flu is very serious and can cause pneumonia, hospitalization, and death.
- Without the flu vaccine, your child has zero added protection if he/she gets exposed. It's not worth the risk. Healthy children who were vaccinated lowered their chance of dying from flu by 65%. That's pretty remarkable.
- A recent study suggests that flu vaccine protected most kids against severe disease even when the vaccine wasn't a perfect match for the virus.

My child is healthy and doesn't need a flu shot.

- Flu viruses mutate constantly, changing yearly.
- Every year, healthy kids who have never caught the flu before, suddenly get it.
- Flu can spread easily at school, while playing with friends, or being out in the community.
- I got my flu shot. I also immunized my kids. As your doctor/nurse, I want your family to also be protected.
- Scarlet died from flu complications at age 5; to her mother's regret, she was not vaccinated. Watch Scarlet's Story and share with clinic staff and parents.

I'm concerned about side effects.

- Vaccines, like any medication, can cause side effects. Most flu effects are mild, e.g., pain or redness in the arm.
- This should go away quickly. If you have any concerns after getting vaccinated, please call us.

I don't want vaccines with thimerosal/mercury

- · Most flu vaccine is thimerosal-free.
- For kids under 3: you'll be getting the vaccine without any thimerosal. Flu vaccine with or without thimerosal is safe and effective.
- If parents are still concerned, you can show this 3 minute video: Is there Mercury in Vaccines? by the Children's Hospital of Philadelphia.

The flu is just like a bad cold—it's not serious.

- Flu viruses are not the same as a cold. When a person catches the flu, they often have a fever and body aches; most also have to miss days of work or school. When complications set in, flu can be life-threatening. While babies, pregnant women, those with certain health conditions, and seniors are at highest risk, even healthy children can die from flu.
- Last year Flu sent 4 million Americans to the doctor 100,000 were hospitalized and 5,000 people died, including 43 children.

My child is afraid of needles.

- · If available, offer the LAIV (nasal spray) flu vaccine.
- Let younger children sit in their parents' laps; practice distraction techniques. Suggest the parent bring a favorite snack, book or toy for comfort.
- Allow an older child to listen to music and ask them to take deep breaths.
- Reassure the parent and their child so they keep calm, and be honest about the pinch.
- Be supportive and offer praise. You can say: "I know you seemed worried about your visit today, but you did it! I'm so proud of you for being so brave! Maybe it will even get a little easier next time."

I don't care so much about flu since COVID-19.

 Flu and COVID are both unpredictable and can be very serious. I recommend vaccination against both. If your child needs a COVID vaccine or booster, it's safe, effective and convenient to get both vaccines today.



California Department of Public Health, Immunization Branch This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC)

VACCINE INCIDENT REPORTING



STATE FLU VACCINE INCIDENT REPORTING PROCESS

- Report to our Program:
 - Data Loss
 - Out of RangeTemperature
 - □ Vaccine left out
- Please Do not report "State Flu Vaccine" to SHOTS.
- Use the most updated Incident report form when reporting the State Flu Vaccine.
- Fill out all sections of the Incident Report

State Purchased Flu Vaccine Storage and Handling Incident Reporting Process

Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Any temperature excursion must be documented and reported to State Flu Vaccine Program. The information reported on storage and handling incidents is used to determine whether a vaccine is likely to be viable and can be administered to patients. Timely and accurate reporting of temperature excursions is essential to a successful determination of vaccine viability.

This information refers to **State Funded Flu vaccine only**. If you have VFC or vaccine from other funding sources in the affected storage unit, report the excursion to those programs and follow program specific reporting procedures. **Do NOT report State Funded Influenza Vaccine temperature excursions to VFC/SHOTS or on MyVFCvaccines.org**.

When is it required to report a temperature excursion?

- *When the temperature goes above 46°F or 8°C for any amount of time.
- *When the temperature goes below 36°F or 2°C for any amount of time.

When is it required to report a vaccine handling incident?

*When vaccine was left out at room temperature for longer than 1 hour or left in cooler and not returned to the refrigerator within 8 hours of being removed.

*When data logger reports cannot be produced (e.g., deleted data logger reports, data logger malfunctions and/or stops logging, vaccine transported without a data logger).





- Notify the Vaccine Coordinator or report the problem to supervisor.
- If needed, transport the vaccine to an alternative unit or storage location in an appropriate cooler. NEVER allow vaccine to remain in a non-functioning unit.
- * Do not turn off the alarm until you have identified and addressed the cause of the temperature excursion.
- Check the basics: storage unit malfunction, storage unit doors not properly closing, data logger settings, power outage.

- *Download the data logger report.
- *Enter a note on the manual temperature log

 *Complete the <u>State-General Fund Incident Report</u>

Document

- *Contact the vaccine manufacturer and request stability information for each vaccine product affected based on this incident. Inform manufacturer if vaccine has experienced previous excursion/ incident.
- *GSK Stability Calculator

GlaxoSmithKline (GSK)	888-825-5249	
Sanofi Pasteur	800-822-2463	
Sequiris	855-358-8966	

*Email the manufacturer stability information, incident report form, and data logger report to: HHSA.CountyFluVaccine@sdcounty.ca.gov

Contact

- *Contact the State Flu Vaccine Coordinator: 619-366-7128 (Monday—Friday, 8am to 5pm)
- ♦ If out of office, contact Sr. Public Health Nurse: 619-980-0419
- *You will receive an email notification from the State Flu Program whether or not the vaccine can be used. After Hours Excursions at Vaccination Event:
- *Follow manufacturer recommendations for use or discontinued use of vaccine. Email the required documents listed above within one business day to HHSA.CountyFluVaccine@sdcounty.ca.gov

VACCINE INCIDENT REPORTING



- Use the most updated Incident report form when reporting the State Flu Vaccine.
- Fill out all sections of the Incident Report

	STORAG	E & HANDLING IN	CIDENT REPORT Label vaccines "DO NOT USE" unt	il furthe	v quidance			
REPORT DATE	ore vaccines in	DISCOVERY DATE AND TIME	NAME OF PERSON REPORTING	PHONE	guidance.			
PRACTICE/CLINIC NAME			PIN	FMAII				
PRACTICE/CENTC NAME			Pin .	EMAL				
Problem:			Cause of the Prob	lem:				
Temperature	above 46.0°F	8.0°C)	☐ Broken/malfunctioned dat	a logger	☐ Power outage			
Temperature				☐ Storage unit Malfunction ☐ Door left open				
☐Vaccine left o	ut – Room tem	perature	☐ Unit unplugged ☐ Compromised 5					
Other:			☐ Vaccine left in cooler long ☐ Other:	er than	8 hours			
Storage Uni	t: Brand/M	ake Name:	Model #:					
		Type of Unit	Unit Grade		For Temperature Stability			
Refrigerator	☐ Stand-ald	ne Under-counter	☐ Pharmaceutical ☐ Comm	nercial	Est. # of water bottles:			
Data logger serial	of the Incide	ent:	Center of unit Other: How often are MIN/MAX cleared? Fected vaccines involved in previously tes:	-	ation Expiration Date			
Please fill out the following information for State Funded Flu Vaccine Only Date and Time excursion occurred: Temperature "F/°C Range Total Min								
Date , time and te List all State Flu va		-						
		rer recommendation for use for Recommendation:	each State Flu vaccine product:					
Case#:		Recommendation:						
Brief summary of	the incident:_							
Action Taken:								
VFC vaccines st	ored in the unit	(Yes/No) If Yes, was inc	cident reported to SHOTS (Yes/No)					
Send the Incide	nt report, Manul	acturer stability report(s), and Da	ta logger report including 24 hours prio	rtothee	xcursion incident to email			
		HHSA.CountyFluVaccine@sc	lcounty.ca.gov within one business day	<i>j</i> .				



Thank you



Araceli Montera, MPH

Araceli.Montera@sdcounty.ca.gov

State influenza Vaccine Program Coordinator

P: 619-679-2686 | HHSA.CountyFluVaccine@sdcounty.ca.gov





Immunization Epidemiology Data Updates

Presented at the San Diego Immunization Coalition (SDIC) Meeting February 1, 2023

Danelle Wallace, MPH

Senior Epidemiologist

Epidemiology & Immunization Services Branch

Public Health Services



COVID-19 Vaccines





Weekly Vaccine Data for 1/26/2023:

Doses received: 10,303,625

Doses administered: 8,513,846

San Diego County Residents Primary Series*: 2,693,247

% Fully Vaccinated Primary Series: 80.5%

Booster Doses Administered to SD County Residents**: 1,518,255

% Eligible with Booster: 60.8%

Bivalent Booster Doses Administered^: 556,351

% with Bivalent Booster: 22.3%

*Primary vaccine series completion is defined as receipt of 2 vaccine doses for persons over the age of 5 who received Pfizer -BioNTech, Moderna, NovaVax, Astrazeneca, or recipient of 2 doses for persons who received unspecified U.S.-authorized or approved COVID-19 vaccine, or receipt of 1 dose for persons who received Janssen. For those 6 months to 4 years of age, primary vaccine series completion is defined a receipt of 3 vaccine doses for persons who received Pfizer-BioNTech, or receipt of 2 doses for

**Booster eligibility is updated each week as the number of San Diego County residents who have completed their primary vacci ne series are eligible to receive a booster dose. Individuals are eligible for a monovalent booster dose if 1) they are 5 years of age and older AND 2) the appropriate time period has passed since completing their primary vaccine series. Additionally, residents may receive a bivalent booster dose if 1) they are 5 years of age and older AND 2) at least 2 months have passed after completing their primary vaccine series.


^Bivalent booster eligibility is updated each week as the number of San Diego County residents are eligible to receive a bivalent booster dose. Individuals are eligible for a bivalent booster dose if 1) they are 5 years of age and older (for a Pfizer bivalent booster) or 6 years of age and older (for a Moderna bivalent booster) AND 2) at least 2 months have passed after completing their primary vaccine series or at least 2 months have passed after their most recent monovalent booster dose.

COVID-19 Vaccines






Vaccinations Administered




The bars show COVID-19 bivalent boosters administered, not individuals vaccinated. The line shows the percent of persons vaccinated with bivalent boosters per the dose and schedule regimen for the vaccine received. The bivalent vaccine was authorized for use in the United States in late August, so the data shown are since the bivalent vaccine became available.

COVID-19 Vaccines






- Nationally, the bivalent booster coverage rate is 15.5%.
- Statewide, the bivalent booster coverage rate is 23.8%.



Influenza Vaccines





Epi IZ PROJECTS



- Media/ad hoc data requests
- Breakthrough analyses COVID
- School Workforce grant coverage rates for childhood immunizations
- CalSRVSS Community respiratory virus surveillance
- COVID-19 vaccine matching projects jails



Contact information:

Danelle Wallace, MPH

Senior Epidemiologist

Epidemiology and Immunization Services Branch

DanelleRuth.Wallace@sdcounty.ca.gov

(619) 629-1698



VFC Program Updates

February 1st, 2023

Mary Rebbert, Senior VFC Field Representative

California Department of Public Health



VFC Clinic Visits – In Person & Virtual

- Compliance Visits: Mostly in-person
 - ➤VFC Representatives review fundamentals of vaccine storage & handling, management, vaccine eligibility screening, and documentation.
 - ➤ Schedule = every other year
- Storage & Handling Visits: Scheduled Visits only
 - ➤ Spot checks focusing on assessing storage & handling practices within the clinic
 - ➤ Schedule = as needed



VFC Clinic Visits – In Person & Virtual

Immunization Quality Improvement for Providers (IQIP)
 Visits: In-person or Virtual

Purpose is to promote & support the implementation of provider-level immunization quality improvement strategies designed to increase vaccine uptake of ACIP recommended vaccines.

Strategies include:

- ➤ Schedule the next immunization visit before the patient leaves the clinic
- ➤ Leverage Registry to increase immunization coverage rates
- ➤ Give a strong vaccine recommendation (HPV for adolescents)
- ➤ Strengthening Vaccine Communication = NEW



VFC Updates – Recertification

- Recertification, Deadline 1/31/2023
 - Please complete all steps in the VFC Recertification process, including completing the required lessons on EZIZ.
 - Not completing VFC Recertification will result in suspension of vaccine ordering and eventual termination from the VFC Program.
 - VFC site will be slow due to high traffic this week, please be patient and try to operate the website in off hours.



2023-2024 Flu Pre-Book – NOW OPEN

- Communication sent out 1/20/2023
- Expected
 Deadline: Feb 3rd
 2023

Expected Product Availability

Actual products that will be available for 2023-2024 VFC Flu Ordering will be dependent upon demand, product availability, and doses approved by the CDC.

Age Group	Product	Presentation	Manufacturer
6 months-18 years	Fluarix [®] *	Inactivated, Quadrivalent, No Preservative, 0.5mL single-dose syringe, 10 pack*	GSK
6 months-18 years	Flucelvax® *	Inactivated, Quadrivalent, No Preservative, 0.5mL single-dose syringe, 10 pack*	Seqirus
6 months-18 years	FluLaval® *	Inactivated, Quadrivalent, No Preservative, 0.5mL single-dose syringe, 10 pack*	GSK
6 months-18 years	Fluzone®*	Inactivated, Quadrivalent, No Preservative, 0.5mL single-dose syringe, 10 pack*	Sanofi
2-18 years	FluMist®	Live Attenuated, Quadrivalent, 0.2mL nasal sprayer	AstraZeneca

^{*}Preservative-free vaccines should be prioritized for administration to pregnant teens under 18 years of age but may also be used in children 3-18 years of age. According to the Health and Safety Code Section 124172, pregnant women or children younger than three years old may only receive vaccine doses that contain trace levels or no mercury.



VFC Shipping Schedule

- Currently no shipment delays
- Future closure dates: 2/20/2023
 - Observance of President's Day



Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine, Merck)

- Available December 2st, 2022
- Information Letter
- Please have offices submit a <u>Brand Switch Form</u>, signed by the Provider of Record, if your offices would like to switch and order this vaccine.
- PCV13 and PCV15 can be used interchangeably according to currently recommended PCV13 dosing and schedules.
- The definition of persons 2-18 years at increased risk of pneumococcal disease who are also recommended for PPSV23 has not changed.



PRIORIX™ (MMR Vaccine, GSK)

- Available December 7th, 2022
- Information Letter
- Please have offices submit a <u>Brand Switch Form</u>, signed by the Provider of Record, if your offices would like to switch and order this vaccine.
- Please note that MMR is now under "Men B" on the order form.
- Although PRIORIX™ is another brand of MMR vaccine, it is recommended to be stored under refrigerator temperatures of between 36° and 46°F (2° and 8°C) per the vaccine manufacturer recommendations.
- We continue to recommend storage of MMR®II (MMR Vaccine, Merck) under freezer temperatures of between -58° and 5°F (-50° and -15°C) per the vaccine manufacturer recommendations.
- Please follow vaccine manufacturer recommendations for storage of all VFC vaccines.



VFA Program

- Webinar is recorded and posted January 2023
- ➤ This webinar will cover VFA program updates, immunization recommendations, and a special presentation from Community Health Centers of the Central Coast to discuss their best practices on PCV20 usage.
- ➤ No open enrollments this year, 2023
- > Ordering for the first quarter is closed, 1/20/2023



VFC Program: KidsVaxGrant 3.0

- Application Dates: 1/12/2023 to 2/3/2023
- This will be the last grant!
- Target outreach population:
- 978 identified VFC registered providers who have not enrolled in myCAvax
- Grant funding opportunities:
- \$10,000 for target VFC providers who enroll in myCAvax and attest to placing a minimum of 1 vaccine order within 30 days of award notification
- \$5,000 supplemental grant to those myCAvax enrollees who elect to opt in to enhance/upgrade their electronic health record system
- Partnership with Physicians for a Healthy California (PHC) offered exclusively to VFC providers
- www.phcdocs.org/Programs/CalVaxGrant



Digital COVID-19 Vaccine Record Portal

In late February 2023, the Digital Vaccine Record (DVR) portal will be enhanced to provide vaccine group recommendations based on an open-source Evaluator.

Vaccine group,
Vaccine, Series, Date
Given, Age Given, and
Clinic that Administered
or transcribed will
continue to be pulled
directly from the registry.



The DVR will evaluate the resident's immunization history and provide recommendations if a vaccine group is complete, has a dose due soon, or has a dose that is overdue.

Need more help?

For other questions, contact:

<u>1-833-422-4255</u>

M-F 8AM-8PM, Sa-Su 8AM-5PM

NOTE: If you need to update or need help locating your DCVR, submit a request through the <u>Virtual Assistant</u>. We're unable to update your DCVR over the phone.







CAIR2 Updates: SDIC Meeting

Date: 02/01/2023

Mary Rebbert, MPH, CHES

Vaccines For Children Program

Senior Field Representative - Southern California Region

CA Department of Public Health, Division of Communicable Diseases

Immunization Branch





Agenda

- CAIR Website has Moved
- San Diego Immunization Registry (SDIR)
- CAIR is now Statewide
- AB1797
- CAIR Enrollment
- CAIR Training Registration
- COVID-19 & Flu IZ Providers
- Immunization Record Requests
- COVID-19 IZ Record Discrepancies
- Medical Exemptions
- Resources



CAIR WEBSITE HAS MOVED


9am-4pm Monday to Thursday

CAIRHelpdesk@cdph.ca.gov

10am-4pm Friday

Phone: 800-578-7889

Fax: 888-436-8320



CAIR Home page: cdph.ca.gov/cair-lcr
LCR page: gov/cair-lcr



immunization information system for California residents.

Announcements:

The California Immunization Registry (CAIR2) is a secure, confidential, statewide computerized



San Diego Immunization Registry (SDIR)

SDIR migration to CAIR2 occurred on April 25, 2022

- SDIR users are now using CAIR2 and no longer using SDIR
- All patient records from SDIR are in CAIR2

Provider Support:

Local CAIR Representatives (LCRs): go.cdph.ca.gov/cair-lcr

CAIR Help Desk

Phone: 800-578-7889 option #9

Email: CAIRHelpDesk@cdph.ca.gov

CAIR Data Exchange Specialists

Email: CAIRDataExchange@cdph.ca.gov



CAIR2 is Now Statewide!

Healthy Futures/RIDE and CAIR2 now share patient records via an automated data connection!

- Healthy Futures/RIDE (HF) still maintains its own IZ Registry and HF users only use the HF Registry, they do not use CAIR2
- HF users can access a CAIR2 patient record via the data connection and add that patient to the HF Registry
- Updates to patient records and new records entered in HF also go into CAIR2 via the data connection






AB1797: Effective January 1, 2023

All California healthcare providers who administer vaccines are required to:

Enter/submit patient vaccination information to a CA Immunization Registry: CAIR2 or Healthy Futures (HF)/RIDE

- CAIR2 users submit to CAIR2; HF/RIDE users submit to HF/RIDE
- Includes all vaccinations given for all ages
- TB test results must also be reported





AB1797 (con't)

Healthcare providers must also enter/submit the <u>Race and Ethnicity</u> for each patient receiving vaccinations to CAIR2 or Healthy Futures/RIDE. This is to support the assessment of health disparities in immunization coverage.

- If a patient prefers not to share this information, the provider is able to select/submit a "Prefer not to say" option in the IZ Registry.
- From 1/1/2023 to 1/1/2026, the law also allows Schools and licensed Childcare facilities to look-up students' COVID-19 vaccination status in the IZ Registry for attendance purposes.

For more information go to our AB1797 FAQs:

https://www.cdph.ca.gov/Programs/CID/DCDC/CAIR/Pages/AB1797-Registry-FAQs.aspx

CAIR Enrollment

Not enrolled? Enroll here

Already enrolled? **Supervisors only:** Update your site/user information – e.g. add users, shot givers

- Not sure of your enrollment status or if your site is enrolled in CAIR2?
 - Contact your LCR




CALIFORNIA IMMUNIZATION REGISTRY



The California Immunization Registry (CAIR2) is a secure, confidential, statewide computerized immunization information system for California residents.

Welcome to the new CAIR informational website!




CAIRHelpdesk@cdph.ca.gov

Phone: 800-578-7889 Fax: 888-436-8320



Existing CAIR Users







COVID-19 & Flu IZ Providers

 If a site is documenting <u>only</u> COVID-19 <u>or</u> COVID-19 and Flu vaccinations in CAIR they will use **My Turn** or submit to CAIR via **Data Exchange**

Using My Turn for Flu-only providers

- New Providers joining CAIR (or existing ones) that give Fluonly can now use My Turn for Fluonly activities. The site does not need to be a Covid provider to use My Turn for Flu.
- My Turn automatically uploads
 COVID-19 and Flu IZ doses in CAIR

My Turn Contact Information

Website:

https://eziz.org/covid/myturn/

My Turn Flu Only Info:

https://eziz.org/covid/myturn/flu/

My Turn Flu Only Enrollment:

https://eziz.org/assets/docs/COVID19/MyTurnFlu-EnrollmentKit2.pdf.

Onboarding email:

myturnonboarding@cdph.ca.gov

Help desk: myturninfo@cdph.ca.gov




Immunization Record Requests

The general public may request their Covid-only record or their full CAIR Immunization Record directly on: cdph.ca.gov/cair

Digital Covid-19 Vaccine Record (DCVR) request:

https://myvaccinerecord.cdph.ca.gov/






Medical Exemptions (ME)

- Through CAIR-ME, providers can issue and manage standardized medical exemptions for children in school or childcare.
- MEs are **not** entered or tracked in CAIR2.
- Sites do not need CAIR2 accounts to enter MEs.
- CAIR-ME Contact: <u>medicalexemptions@cdph.ca.gov</u>.

Please visit the CAIR-ME website for more information:





CAIR Home page: cdph.ca.gov/cair

Local CAIR2 Reps for San Diego County

https://www.cdph.ca.gov/Programs/CID/DCDC/CAIR/Pages/CAIR-users-LCR.aspx

San Diego Immunization Registry	Local CAIR Rep (LCR):	San Diego
(SDIR) Region	Giselle Garcia	
	Phone: 559-228-5804	
	Email: giselle.garcia@cdph.ca.gov	
	Karla Corado	
	Phoe: 213-351-7472	
	Email: kcorado@ph.lacounty.gov	



CAIR2 Contact Information

Local CAIR Representatives (LCRs): go.cdph.ca.gov/cair-lcr

CAIR Help Desk

Phone: 800-578-7889 option #9

Email: <u>CAIRHelpDesk@cdph.ca.gov</u>

CAIR Data Exchange Specialists

Email: <u>CAIRDataExchange@cdph.ca.gov</u>

Medical Exemptions (ME)

Email: MedicalExemptions@cdph.ca.gov

COVID Call Center

Phone: 833-502-1245

Email: COVIDCallCenter@cdph.ca.gov

Thank you!

Personnel Updates - Vacancies

- VFC Field Representative New 1/27/2023
 - Job Link
- Local CAIR2 Rep San Diego New 1/27/2023
 - Job Link

SoCal Region Staff Contacts

- Mary Rebbert, SR Field Representative <u>Mary.Rebbert@cdph.ca.gov</u> 619-838-6360
- Melissa Thun, JR Field Representative <u>Melissa.Thun@cdph.ca.gov</u> 213-407-2878
- Manny Mones, Field Representative San Diego County & Imperial County <u>Manny.Mones@cdph.ca.gov</u> 619-609-6206
- Carol Connell, Field Representative San Bernardino County Carol.Connell@cdph.ca.gov 619-772-1935
- Michelle Miranda, Field Representative SoCal Region Float Michelle.Miranda@cdph.ca.gov 619-577-2247

Local CAIR Reps:

- Ashley Diaz Imperial, Riverside & San Bernardino Counties Ashley.Diaz@cdph.ca.gov
- Angelina Carrillo, Orange County
 In Training
- Marisol Delgado CAIR Trainer marisol.delgado@cdph.ca.gov





2023 SDIC General Meeting Series

Every first Wednesday of even months from 12:30pm – 3:00pm

Next Meeting: Wed. April 5th, 2023

Save the Date: 4/5, 6/7, 8/2, 10/4, 12/1

COC Chambers 5520 Overland Avenue San Diego, CA 92123

